Esperion Therapeutics, Inc.ESPRNASDAQ
Loading
Operating Expenses Over TimeStable
Percentile Rank64
3Y CAGR-2.1%
5Y CAGR-9.2%
Year-over-Year Change
Expenses from normal business operations (SG&A, R&D, etc.)
3Y CAGR
-2.1%/yr
vs +2.7%/yr prior
5Y CAGR
-9.2%/yr
Recent acceleration
Acceleration
-4.9pp
Decelerating
Percentile
P64
Within normal range
vs 5Y Ago
0.6x
Contraction
Streak
1 yr
Consecutive growthStable
| Period | Value | YoY Change |
|---|---|---|
| 2025 | $213.64M | +2.1% |
| 2024 | $209.31M | -8.4% |
| 2023 | $228.63M | +0.3% |
| 2022 | $228.01M | -21.6% |
| 2021 | $290.96M | -16.0% |
| 2020 | $346.55M | +43.5% |
| 2019 | $241.47M | +18.0% |
| 2018 | $204.59M | +21.1% |
| 2017 | $168.98M | +121.9% |
| 2016 | $76.15M | - |